Skip to main content
Fig. 4 | Molecular Cancer

Fig. 4

From: An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer

Fig. 4

The transcriptional activation of ALDH2 is cooperatively regulated by NFYA and EHMT2. A The expression levels of epigenetic enzymes in NCI-H460 and NCI-H460/PTX cells by gene microarray analysis. B Left: Epigenetic enzymes and their corresponding inhibitors. Right: The protein expression levels of ALDH2 in NSCLC/PTX cells treated with epigenetic enzyme inhibitors. C ALDH2 protein levels in NSCLC/PTX cells treated with EHMT2 inhibitors (UNC0638, UNC0642, UNC0631) and a JMJD inhibitor (JIB04). D-E Luciferase activity elicited by the ALDH2 P1 promotor in NSCLC/PTX cells after overexpression of NFYA or treatment with epigenetic enzyme inhibitors. **p < 0.01, ***p < 0.001, as compared to the promotor group. ##p < 0.01, ###p < 0.001, as compared to the NFYA overexpression group. F Left: ChIP-Seq summary plot of H3K9me2-binding intensities across H3K9me2 peaks in NCI-H460 and NCI-H460/PTX cells. Right: ChIP-Seq summary plot of Ac-H3-binding intensities across Ac-H3 peaks in NCI-H460 and NCI-H460/PTX cells. G Top: ChIP assay for the H3K9me2 modification involved in ALDH2 in NCI-H460 and NCI-H460/PTX cells. Middle: ChIP assay for the Ac-H3 modification involved in ALDH2 in NCI-H460 and NCI-H460/PTX cells. Bottom: ChIP assay for the NFYA modification involved in ALDH2 in NCI-H460 cells. **p < 0.01, ***p < 0.001, as compared to the control group

Back to article page